Sanofi Sponsored ADR Stock News

ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care

Sanofi delivered strong Q3 results despite currency headwinds. The company's dependence on Dupixent is increasing. A broad immunology pipeline and the Blueprint Medicines acquisition should help address the issue.

Sanofi (SNY) remains a Buy, driven by Dupixent's robust growth and expanding indications, notably with the recent COPD launch. SNY's Q3 saw total revenues rise 7% CER to €12.43 billion, with Dupixent contributing over €4 billion for the first time. Beyond Dupixent, SNY is diversifying with specialty launches like Altuviiio in hemophilia and Beyfortus in RSV, plus a strong pipeline and share buy...

Sanofi (SAN:CA) Q3 2025 Earnings Call Transcript

Sanofi stock jumped early Friday on better-than-expected third-quarter sales and earnings, and a strong showing from Dupixent.

Pharmaceutical launches and increased demand for its blockbuster Dupixent drug lifted net sales by 7% in the third quarter.

France's Sanofi reported a third-quarter profit that beat analysts' expectations on Friday, boosted by strong demand for its anti-inflammatory drug Dupixent and newer medicines.